All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
34 matching companies
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
AUBE00 is an oral macrocyclic peptide in Phase 1. LUNA18 was discontinued in 2025; the company report confirms oral absorption in humans.
CID-078, from the MXMO macrocycle platform, is an oral cyclin A/B RxL inhibitor in Phase 1; CID-165 targets cyclin D1.
Uses AI to design macrocycles de novo. The website lists oral / cell-permeable approaches and an α4β7 IBD program; website percentages are not converted into clinical-stage assignments.
RaniPill is a swallowable robotic capsule. RT-101 octreotide is a historical human development program whose current activity is unconfirmed, recorded separately from conventional intestinal permeation enhancement.
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
PAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
The 2026-02-03 announcement reports first dosing in the Phase 1/2 NEO-811 renal cancer trial. The company pipeline identifies ARNT/HIF-1β as its target and lists pharmaceutical collaborations.
The website and 2026 ASCO materials identify ST-01156 as an RBM39 molecular glue degrader in Phase 1 studies in solid tumors including Ewing sarcoma and hepatocellular carcinoma.
A March 2026 announcement reports the first patient treated in Phase 1/2 TRI-611. A September 2026 Nature paper describes its distinctive ALK–CRBN interface and preclinical intracranial tumor models.
The website describes CT7439 as both a CDK12/13 inhibitor and Cyclin K glue degrader. Its Phase 1/2 trial, NCT06600789, uses oral capsules.
A 2026-06-16 Rigel announcement confirms completion of an exclusive global development, manufacturing, and commercialization license for VEPPANU from Arvinas/Pfizer, effective 2026-06-11.
Develops cancer and infectious disease programs using immunotherapy and mRNA platforms; COMIRNATY is a named product with regulatory validation.
Gyre completed its acquisition of Cullgen on 2026-05-04; they are consolidated into one company record.
The website identifies HP518 as an oral AR PROTAC. Enrollment in China Phase 2 is complete, Australian Phase 1 is complete, and China combination Phase 1/2 authorization was obtained in November 2025.
A May 2026 financing announcement describes DEG6498 as an oral HuR molecular glue inducing a CRBN–HuR interaction. First dosing occurred in November 2025; Phase 1 dose escalation is ongoing.
The website lists GLB-001 Phase 1 in U.S. AML/HR-MDS and Chinese myeloid tumors, and GLB-002 Phase 1 in Chinese NHL.
An original 2025 ESMO abstract describes QLH12016 as an oral AR PROTAC, with data through February 2025 from 36 patients with mCRPC.
The official pipeline explicitly lists HJ-002 and HJ-004 as EGFR PROTACs for NSCLC and advanced cancers, respectively.
DT2216 is a VHL-recruiting BCL-XL PROTAC. An original 2025 Phase 1 paper in 20 patients reports human PK and peripheral leukocyte BCL-XL reduction. NCI lists combination studies in ovarian and fibrolamellar liver cancers.
Founded in July 2021, the company focuses on innovative mRNA drugs and adjuvants, with oncology, infectious disease, and other mRNA programs.
Aanastra discloses PEP-CAR, an anti-CD19 in vivo CAR-T strategy combining engineered RNA and targeting peptides for cancer and autoimmune disease. The public website does not establish a registered clinical program or validated patient outcomes.
Coverage expands from sourced records; this database does not claim all biopharma companies.
